Cardiovascular Therapeutics Targets on the NO–sGC–cGMP Signaling Pathway: A Critical Overview

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|13|9|1207-1214

ISSN： 1389-4501

Source： Current Drug Targets, Vol.13, Iss.9, 2012-08, pp. : 1207-1214

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting NO/cGMP Signaling in the CNS for Neurodegeneration and Alzheimer’s Disease

By  

Current Medicinal Chemistry, Vol. 23, Iss. 24, 2016-07 ,pp. : 2770-2788

Bentham Science Publishers

Access to resources Recommend Favorite

The nitric oxide-cGMP signaling pathway plays a significant role in tolerance to the analgesic effect of morphine

By Ozdemir Ercan   Bagcivan Ihsan   Durmus Nedim   Altun Ahmet   Gursoy Sinan  

Canadian Journal of Physiology and Pharmacology, Vol. 89, Iss. 2, 2011-02 ,pp. : 89-95

NRC Research Press

Access to resources Recommend Favorite

NO Signaling Through cGMP in Renal Tissue Fibrosis and Beyond: Key Pathway and Novel Therapeutic Target

By  

Current Medicinal Chemistry, Vol. 15, Iss. 14, 2008-06 ,pp. : 1396-1406

Bentham Science Publishers

Access to resources Recommend Favorite

Nipradilol inhibits apoptosis by preventing the activation of caspase-3 via S-nitrosylation and the cGMP-dependent pathway

By Tomita H.   Nakazawa T.   Sugano E.   Abe T.   Tamai M.  

European Journal of Pharmacology, Vol. 452, Iss. 3, 2002-10 ,pp. : 263-268

Elsevier

Access to resources Recommend Favorite

cGMP Signaling, Phosphodiesterases and Major Depressive Disorder

By  

Current Neuropharmacology, Vol. 9, Iss. 4, 2011-12 ,pp. : 715-727

Bentham Science Publishers

Access to resources Recommend Favorite